Therapeutic Host Anticancer Immune Response through Photoimmunotherapy for Head and Neck Cancer May Overcome Resistance to Immune Checkpoint Inhibitors.

ABSTRACT:

Introduction

Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy that directly kills cancer cells while producing a therapeutic host anticancer immune response. The activation of host immunity using NIR-PIT can enhance the effects of immune checkpoint inhibitors (ICIs) in animal experimental models; however, there have been no reports of this phenomenon in humans. Furthermore, by activating host immunity using NIR-PIT in patients who have become resistant to ICIs, the effects of ICIs can be restored.

Case presentation

A 56-year-old male experienced local recurrence after chemoradiotherapy for maxillary sinus cancer (cT4bN0M0). The disease had progressed following ICI antiPD-1 antibody therapy. He underwent NIR-PIT for four cycles; however

SUBMITTER: Koyama S 

PROVIDER: S-EPMC11521423 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature